The weekly litigation news digest is live. Subscribe now
Methods Of Treating Bacterial Infections - EP3565551
The patent EP3565551 was granted to Melinta Therapeutics on Mar 20, 2024. The application was originally filed on Jan 8, 2018 under application number EP18735813A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3565551
- Application Number
- EP18735813A
- Filing Date
- Jan 8, 2018
- Status
- Granted And Under Opposition
- Feb 16, 2024
- Publication Date
- Mar 20, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Combination therapy of vaborbactam and meropenem for treating urinary tract infections (UTIs) and acute pyelonephritis (AP) in patients with severe comorbidities. The combination provides enhanced efficacy against carbapenem-resistant Enterobacteriaceae (CRE) pathogens, particularly in patients with high-risk profiles such as those with SIRS, severe renal impairment, or a Charlson comorbidity score ≥3. The combination achieves superior clinical outcomes compared to standard meropenem-vaborbactam or piperacillin-tazobactam combinations.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (5) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents